NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 135.19M +9.3% |
| Revenue (ttm) | n/a -51.8% |
| Net Income | -38.64M |
| EPS | -1.87 |
| Shares Out | 25.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,013 |
| Open | 5.32 |
| Previous Close | 5.36 |
| Day's Range | 5.29 - 5.66 |
| 52-Week Range | 3.20 - 12.99 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 16.00 (+195.2%) |
| Earnings Date | May 15, 2026 |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra... [Read more]
Financial Performance
In 2025, NTHI's revenue was $39,990, a decrease of -51.82% compared to the previous year's $83,000. Losses were -$62.15 million, 422.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NTHI stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 195.20% from the latest price.
News
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
DENVER, May 19, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com) – NeOnc Technologies (NASDAQ:NTHI), a clinical-stage biotechnology company focused on treatments for central nervous system (CNS) can...
NeOnc Technologies initiated with a Buy at Alliance Global
Alliance Global initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $13 price target The company is focused on developing intranasally-delivered small molecules for brain tumors, nam...
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
CALABASAS, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company advancing two Phase 2 progra...
NeOnc Technologies initiated with a Buy at Maxim
Maxim initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $20 price target
Biotech's Next Wave May Already be in Motion
DENVER, May 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com and NeOnc Technology) - The biotech and pharma sector is entering one of its most pivotal periods in years, where insider conviction, la...
Where Executives Are Doubling Down on Their Companies' Fortunes
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts through the noise: insiders putting real money ...
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovat...
NeOnc Technologies initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $15 price target The company is taking a multi-pronged approach by improving central nervous system…
NeOnc Technologies files to sell 680,558 shares of common stock for holders
17:16 EDT NeOnc Technologies (NTHI) files to sell 680,558 shares of common stock for holders
NeOnc Technologies files $300M mixed securities shelf
13:01 EDT NeOnc Technologies (NTHI) files $300M mixed securities shelf
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
NeOnc Technologies appoints Choi as Chief Accounting Officer
NeOnc Technologies (NTHI) Holdings has appointed David Choi as Chief Accounting Officer. In this role, Choi is responsible for overseeing the Company’s accounting, financial reporting, internal contro...
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
Dallas, Texas--(Newsfile Corp. - March 12, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Ne...
NeOnc Technologies reports Phase 1 dose-escalation results for NEO212
NeOnc Technologies (NTHI) Holdings announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company’s novel oral bio-conjugated therapy and will host a conferenc...
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing no...
NeOnc Technologies files to sell 2.95M shares of common stock for holders
16:50 EST NeOnc Technologies (NTHI) files to sell 2.95M shares of common stock for holders
NeOnc Technologies secures strategic PIPE investment from Cinctive Capital
NeOnc Technologies (NTHI) announced that it has entered into a securities purchase agreement for a private investment in public equity for the purchase and sale of up to 2,222,222 shares…
NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
Investment led by Cinctive Co-Founder Richard Schimel underscores institutional confidence in NeOnc's biotech pipeline Investment led by Cinctive Co-Founder Richard Schimel underscores institutional c...
Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
Dallas, Texas--(Newsfile Corp. - January 9, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). Stonegate Capital Partners initiates their coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: ...
NeOnc Technologies announces updated NEO100 clinical results
NeOnc Technologies (NTHI) announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-...
NeOnc Technologies Reports Updated Clinical Results
CALABASAS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing no...
NeOnc Technologies files to sell 111.7K shares of common stock for holders
07:57 EST NeOnc Technologies (NTHI) files to sell 111.7K shares of common stock for holders
NeOnc Technologies announces preclinical findings from USC collaboration
NeOnc Technologies (NTHI) announced newly published preclinical findings from a research collaboration at the University of Southern California. The study, now available on bioRxiv, demonstrates that ...